Nice post and the SEC action bodes well for UEEC i
Post# of 586
(Total Views: 457)
Posted On: 06/16/2022 3:19:11 PM
Re: whytestocks #171
Nice post and the SEC action bodes well for UEEC in several ways! IMO!
1. Revcover from short manipulation and net influx of revenue from the form CEO
"In a separate settlement agreement between the Commission and Mr. Douglas Beplate, the company’s former Chief Executive Officer and a Director, Mr. Beplate will, among other things, make disgorgement payments to the company totaling $1,020,000 over the next six months."
2. PPS bringing in new money!
3. Run up now for our investment company that appear to have put their money on hold? See the company 6-28-2021 equity financing update!
To fund these and other R&D initiatives, on June 25th, UHP entered in an Common Stock Purchase Agreement with Triton Funds LP under which Triton Funds will invest $4,000,000 to purchase approximately 4,525,000 of UHP’s common shares. In addition, Triton Fund will have the right to invest an additional $2,000,000 to purchase approximately 2,263,000 UHP common shares over the next two years. These investments are subject to the SEC approval of a Registration Statement which UHP is filing today.
Casey Barraza of Triton Funds commented: “UHP is poised to offer a disruptive technology to the human surgical market that, if FDA approved, we believe has the potential to capture significant market share in the hemostatic market. We are particularly excited about the potential to offer a variety of HemoStyp formats that will position UHP to successfully challenge the established market leaders.”
1. Revcover from short manipulation and net influx of revenue from the form CEO
"In a separate settlement agreement between the Commission and Mr. Douglas Beplate, the company’s former Chief Executive Officer and a Director, Mr. Beplate will, among other things, make disgorgement payments to the company totaling $1,020,000 over the next six months."
2. PPS bringing in new money!
3. Run up now for our investment company that appear to have put their money on hold? See the company 6-28-2021 equity financing update!
To fund these and other R&D initiatives, on June 25th, UHP entered in an Common Stock Purchase Agreement with Triton Funds LP under which Triton Funds will invest $4,000,000 to purchase approximately 4,525,000 of UHP’s common shares. In addition, Triton Fund will have the right to invest an additional $2,000,000 to purchase approximately 2,263,000 UHP common shares over the next two years. These investments are subject to the SEC approval of a Registration Statement which UHP is filing today.
Casey Barraza of Triton Funds commented: “UHP is poised to offer a disruptive technology to the human surgical market that, if FDA approved, we believe has the potential to capture significant market share in the hemostatic market. We are particularly excited about the potential to offer a variety of HemoStyp formats that will position UHP to successfully challenge the established market leaders.”
(0)
(0)